H. Mallo

发表

Exploring supportive care and information needs through a proposed eHealth application among melanoma patients undergoing systemic therapy: a qualitative study

R. Cornet, L. V. van de Poll-Franse, S. Medlock, 2022, Supportive Care in Cancer.

Phase I Clinical Study With Multiple Peptide Vaccines in Combination With Tetanus Toxoid and GM-CSF in Advanced-stage HLA-A*0201-positive Melanoma Patients

J. Haanen, J. Sein, F. Vyth-Dreese, 2007, Journal of immunotherapy.

Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)

A. Broeks, K. Sikorska, E. Rozeman, 2019, Melanoma research.

Immunotherapy Bridge 2019 and Melanoma Bridge 2019: meeting abstracts

Infante, K. Sikorska, M. Sznol, 2020, Journal of Translational Medicine.

Brain metastases in patients with renal cell cancer receiving new targeted treatment.

H. Helgason, A. van den Eertwegh, H. Droogendijk, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immuun- en targeted therapie

J. Haanen, W. Uyterlinde, H. Mallo, 2021, Leerboek oncologieverpleegkunde.

Switch to checkpoint inhibition (CPI) after targeted therapy (TT) at time of progression or during ongoing response: A retrospective analysis of patients with advanced BRAF mutated melanoma.

E. Rozeman, C. Blank, J. Haanen, 2018, Annals of Oncology.

Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma

M. Kersten, G. Groenewegen, S. Horenblas, 2003, British Journal of Cancer.

Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma : a consecutive study

W. Meinhardt, S. Horenblas, A. Bex, 2006 .

Exploring supportive care and information needs through a proposed eHealth application among melanoma patients undergoing systemic therapy: a qualitative study

R. Cornet, L. V. van de Poll-Franse, S. Medlock, 2022, Supportive Care in Cancer.

T-Cell Immune Function in Tumor, Skin, and Peripheral Blood of Advanced Stage Melanoma Patients: Implications for Immunotherapy

J. Drijfhout, J. Haanen, C. M. van der Horst, 2011, Clinical Cancer Research.

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

A. Broeks, T. Schumacher, K. Sikorska, 2018, Nature Medicine.

Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up

T. Schumacher, M. V. van Buuren, J. Beijnen, 2020, Journal for ImmunoTherapy of Cancer.

Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.

J. Schellens, H. Rosing, J. Beijnen, 2011, Journal of analytical toxicology.

The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand–foot syndrome

J. Schellens, J. Beijnen, C. Blank, 2013, European Journal of Clinical Pharmacology.

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

J. Berkhof, J. Haanen, H. Helgason, 2008, British Journal of Cancer.

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.

K. Sikorska, J. Haanen, H. Eriksson, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

On the Role of Melanoma-Specific CD8+ T-Cell Immunity in Disease Progression of Advanced-Stage Melanoma Patients

T. Schumacher, J. Haanen, M. Gallee, 2004, Clinical Cancer Research.

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

K. Shannon, A. Broeks, T. Schumacher, 2021, Nature Medicine.

Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study

J. Haanen, W. Boogerd, L. Dewit, 2005, Cancer Immunology, Immunotherapy.

A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor

J. Haanen, S. Horenblas, A. Bex, 2005, Cancer Immunology, Immunotherapy.

Extended Continuous Oral Temozolomide in Patients with Progressive Metastatic Renal Cell Carcinoma Not Responding to Interferon Alpha 2b

H. van Tinteren, S. Horenblas, A. Bex, 2005, Journal of chemotherapy.

The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand–foot syndrome

J. Schellens, J. Beijnen, C. Blank, 2013, European Journal of Clinical Pharmacology.

Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study.

W. Meinhardt, S. Horenblas, A. Bex, 2006, European urology.

290 A phase 2 study of pegylated interferon alfa-2B (peg-intron) for patients with metastatic renal cell carcinoma after removal of the primary tumour

S. Horenblas, A. Bex, M. Kerst, 2004 .

Downsizing of locally advanced stage III (bulky) BRAF V600E/K melanoma with combination targeted therapy to achieve R0 resection

D. Peeper, C. Blank, J. Haanen, 2017 .

MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial

C. Blank, R. de Boer, J. Haanen, 2022, Immuno-Oncology Technology.

3-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) + nivolumab (NIVO) in macroscopic stage III melanoma (OpACIN trial)

T. Schumacher, K. Sikorska, C. Blank, 2019, Annals of Oncology.

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

A. Broeks, T. Schumacher, K. Sikorska, 2018, Nature Network Boston.

An eHealth App (CAPABLE) Providing Symptom Monitoring, Well-Being Interventions, and Educational Material for Patients With Melanoma Treated With Immune Checkpoint Inhibitors: Protocol for an Exploratory Intervention Trial

M. Peleg, D. Glasspool, R. Cornet, 2023, JMIR research protocols.

T-Cell Immune Function in Tumor, Skin, and Peripheral Blood of Advanced Stage Melanoma Patients: Implications for Immunotherapy

J. Drijfhout, J. Haanen, C. M. van der Horst, 2011, Clinical Cancer Research.

Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.

J. Schellens, H. Rosing, J. Beijnen, 2011, Journal of analytical toxicology.